Noticias

Compartir en Facebook Compartir en Twiter Compartir en Menéame Compartir en Linkedin Suscribirse a nuestra RSS

Francia realizará un estudio de 2 años en el que ofrecerá cannabis de forma gratuita

042410284" title="" target="">a decree announcing the experiment , which enthusiasts and patients alike were waiting for, officially. According to its announcement, up to 3,000 patients will participate and will be eligible to receive the free product. 

Nicolas Authier, a university professor and chairman of the medical cannabis committee of the French Agency for the Safety of Medicines and Health Products (or L"Agence nationale de sécurité du medicament et des produits de santé [ANSM]), said in an interview with Marijuana Business Daily that believes that "an invitation to tender for the selection of cannabis-based products" will arrive soon, probably within a month, and that the suppliers "will probably be foreign ... in collaboration with pharmaceutical laboratories established in France and authorized for narcotics ". "

"Five more months of work before the first prescriptions," he added, "but France is now officially committed to access to medical cannabis."

Currently, the French government estimates that the first free prescriptions could come out from March 2021. As of now, there is a two-year time limit for the experiment, as it is scheduled for March 21, 2021. o using the first recipe, whichever comes first. It will be supervised by the Ministry of Health and Solidarity. 

There are still some stipulations for the program that have not yet been decided, and will be outlined by the director general of the French Agency for the Safety of Medicines and Health Products. Among the issues to be decided are the shape and specifications of cannabis-based products, including characteristics and composition; the list of conditions that will be eligible to participate; and procedures for storing, distributing, importing and controlling cannabis. 

Companies that decide to participate in this new medical cannabis experiment will be responsible for providing their own product for free, and although the cannabis will be free, it will have to comply with pharmaceutical standards such as Good Manufacturing Practices and other regulations. has launched the French government. 

The ANSM will be in charge of implementing a patient registry that will be updated, with the consent of the patients, by doctors and pharmacies.

There are also some restrictions that could prevent patients from accessing this agreement. As is the case throughout Europe, medical cannabis will not be distributed for free. It is not given as an alternative to other drugs of choice, but as a last resort. 

In addition, doctors and pharmacies who want to get involved will have to complete a training program, then volunteer for the trial, and companies that are interested in getting involved will have to provide their own cannabis. In addition, the French parliament has yet to approve a budget for the program. 

Still, regardless of these potential setbacks and the fact that cannabis in general is prescribed conservatively in France, this groundbreaking experiment could set the stage for socialized cannabis medicine around the world.